Mergers & acquisitions
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
Under the terms of their merger agreement, the deal can be terminated at any time. Know what happened between Valo Health & Khosla Ventures before the merger.
AcelRx Pharmaceuticals and Kala Pharmaceuticals both shared acquisition news on Monday. Here’s a closer look at each of the acquisition announcements.
Life sciences veteran Thomas Brock is helming a new therapeutic pipeline at Notable Labs, a company that has primarily been known for its oncology-testing services.
Organon is paying $75 million upfront, taking on about $9 million of Forendo debt, and up to $270 million in various development and regulatory milestones.
Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.
Biohaven and Pfizer have partnered to market the Nurtec migraine medicine outside the U. S. once approved by global regulatory organizations. Here’s more about it.
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
The merger between Blade Therapeutics and Biotech Acquisition Company will provide the company with $254.3 million to drive the development of cudetaxestat.
For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.
PRESS RELEASES